Sophia Stock

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.

Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.

Journal: Blood advances
Published: July 15, 2025

Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers.

Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers.

Journal: Blood advances
Published: July 15, 2025

Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research.

Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research.

Journal: Methods in cell biology
Published: January 17, 2025

Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy.

Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy.

Journal: Leukemia
Published: January 11, 2025

Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma.

Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma.

Journal: HemaSphere
Published: July 11, 2024

Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours.

Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours.

Journal: Nature biomedical engineering
Published: March 19, 2024

Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.

Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.

Journal: Nature communications
Published: December 05, 2023

Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.

Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.

Journal: Cancer immunology, immunotherapy : CII
Published: November 11, 2023

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.

Journal: Science advances
Published: September 22, 2023

Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.

Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.

Journal: Blood
Published: August 16, 2023

PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.

PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.

Journal: Nature
Published: May 22, 2023

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.

Journal: Journal for immunotherapy of cancer
Published: April 16, 2023
Showing 1-12 of 27

Last Updated: 09/26/2026